DOCSLIB.ORG

Piperidine Derivatives Piperidinderivate Derives De Piperidine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Piperidine Derivatives Piperidinderivate Derives De Piperidine (19) TZZ_¥Z_T (11) EP 1 669 350 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/58 (2006.01) C07D 401/06 (2006.01) 29.02.2012 Bulletin 2012/09 C07D 401/14 (2006.01) C07D 401/02 (2006.01) C07D 401/12 (2006.01) C07D 409/12 (2006.01) (2006.01) (2006.01) (21) Application number: 04787951.5 A61K 31/4545 A61K 31/496 A61K 31/454 (2006.01) A61K 31/4523 (2006.01) A61K 31/4535 (2006.01) A61K 31/506 (2006.01) (22) Date of filing: 21.09.2004 A61P 43/00 (2006.01) A61P 3/04 (2006.01) A61P 3/10 (2006.01) A61P 5/00 (2006.01) A61P 3/06 (2006.01) A61P 19/06 (2006.01) A61P 9/10 (2006.01) A61P 9/04 (2006.01) A61P 9/12 (2006.01) (86) International application number: PCT/JP2004/013768 (87) International publication number: WO 2005/028438 (31.03.2005 Gazette 2005/13) (54) PIPERIDINE DERIVATIVES PIPERIDINDERIVATE DERIVES DE PIPERIDINE (84) Designated Contracting States: • TOKITA, Shigeru, AT BE BG CH CY CZ DE DK EE ES FI FR GB GR c/o Tsukuba Research Institute HU IE IT LI LU MC NL PL PT RO SE SI SK TR Tsukuba-shi, Designated Extension States: Ibaraki 3002611 (JP) LT LV • KANATANI, Akio, c/o Tsukuba Research Institute (30) Priority: 22.09.2003 JP 2003330758 Tsukuba-shi, Ibaraki 3002611 (JP) (43) Date of publication of application: 14.06.2006 Bulletin 2006/24 (74) Representative: Rollins, Anthony John et al Merck Sharp & Dohme Limited (73) Proprietor: MSD K.K. European Patent Department Chiyoda-ku Hertford Road Tokyo Hoddesdon 102-8667 (JP) Hertfordshire EN11 9BU (GB) (72) Inventors: (56) References cited: • OHTAKE, N. WO-A1-2004/037257 WO-A2-02/076925 Tsukuba Res. Inst. Banyu Pharmaceutical WO-A2-02/099388 WO-A2-2004/069792 Ibaraki 300-2611 (JP) JP-A- 5 078 316 JP-A- 10 324 695 • MIZUTANI, Sayaka, JP-A- 2001 522 836 c/o Tsukuba Research Institute Tsukuba-shi Ibaraki 3002611 (JP) • YOSHIMOTO, Ryo, c/o Tsukuba Research Institute Tsukuba-shi, Ibaraki 3002611 (JP) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 669 350 B1 Printed by Jouve, 75001 PARIS (FR) (Cont. next page) EP 1 669 350 B1 • DATABASECA[Online]CHEMICALABSTRACTS SERVICE, COLUMBUS, OHIO, US; LUBISCH, WILFRIED ET AL: "Preparation of 2- phenylbenzimidazoles as poly(ADP-ribose) polymerase inhibitors." XP002520491 retrieved from STN Database accession no. 2000:314677 & WO 00/26192 A1 (BASF AKTIENGESELLSCHAFT, GERMANY) 11 May 2000 (2000-05-11) • DATABASECA[Online]CHEMICALABSTRACTS SERVICE, COLUMBUS, OHIO, US; GOEL, OM P.: "Trialkylsilyl esters of 6-(substituted amino) phenyl-1, dihydro-2-oxonicotinic acid and conversion to the corresponding acid chlorides" XP002520492 retrieved from STN Database accession no. 1976:543094 & US 3 951 982 A (GOEL, OM P.) 20 April 1976 (1976-04-20) Remarks: Thefilecontainstechnicalinformationsubmittedafter the application was filed and not included in this specification 2 EP 1 669 350 B1 Description TECHNICAL FIELD 5 [0001] The present invention relates to a novel piperidine derivative, to a histamine-H3 receptor antagonist containing the novel piperidine derivative as an active ingredient thereof, and to a preventive or remedy for metabolic system diseases, circulatory system diseases, central or peripheral nervous system diseases. BACKGROUND ART 10 [0002] It has been known that, in organisms such as typically mammals, histamine that is a physiologically-active endogenous factor functions as a neurotransmitter and has extensive pharmacological activities (for example, see Life Science, 17,1975, 503 (1975)). Immunohistochemical studies have made it clear that a histamine-agonistic (producing) cell body exists in the nodal papillary nucleus in a posterior hypothalamic region and that histamine nerve fibers project 15 histamine in an extremely broad range in the brain, which supports various pharmacological effects of histamine (for example, see Journal of Comprehensive Neurology, 273, 283). The existence of histamine-agonistic nerves in the nodal papillary nucleus in a posterior hypothalamic region suggests that histamine may have an important role in control of physiological functions relating to brain functions, especially to hypothalamic functions (sleep, vigilance rhythm, incretion, eating and drinking action, sexual action, etc.) (for example, see Progress in Neurobiology, 63,637 (2001)). The existence 20 of histamine projection to the brain region that relates to vigilance sustenance, for example, to cerebral cortex suggests the role of histamine in control of vigilance or vigilance-sleep cycle. The existence of histamine projection to many peripheral structures such as hippocampus and amygdaloid complex suggests the role of histamine in control of auto- nomic nerves, emotion, control of motivated action and learning/memory process. [0003] On the other hand, when released from producing cells, histamine acts with a specific polymer that is referred 25 to as a receptor on the surface of a cell membrane or inside a target cell, therefore exhibiting its pharmacological effects for control of various body functions. Heretofore, four types of histamine receptors (H1 to H4) have been found In particular, the presence of a histamine receptor that participates in the central and peripheral nervous functions, a histamine-H3 receptor, has been shown by various pharmacological and physiological studies (for example, see Trends in Pharmacological Science, 8, 24 (1986)); and recently, human and rodent histamine-H3 receptor genes have been 30 identified and their existence has been made clear (for example, see Molecular Pharmacology, 55, 1101 (1999)). It is shown that a histamine-H3 receptor exists in the presynaptic membrane of central or peripheral neurocytes and functions as a self-receptor, therefore controlling the liberation of histamine and controlling the release of other neurotransmitters. Specifically, it is reported that a histamine-H3 receptor agonist, or its antagonist or inverse-agonist (generically referred to as antagonist) controls the release of histamine, noradrenaline, serotonin, acetylcholine or dopamine from nerve 35 ending For example, the release of these neurotransmitters is inhibited by an agonist such as (R)-(α)-methylhistamine, and the release of these neurotransmitters is promoted by an antagonist or inverse-agonist such as thioperamide (for example, see Trends in Pharmacological Science, 19,177 (1998)). Recent studies have shown that a histamine-H3 receptor has extremely high homeostatic activities (endogenous agonistic factor, e.g., activity observed in the absence of histamine) in the receptor-expressing cells/tissues or in a membrane fraction derived from the expressing cells/tissues 40 and even in living bodies (for example, see Nature, 408, 860). It is reported that these homeostatic activities are inhibited by an antagonist or an inverse-agonist. For example, a homeostatic self-receptor activity is inhibited by thioperamide or syproxyfan, and, as a result, the release of neurotransmitters from nerve ending, for example, the release and liberation of histamine from it is thereby promoted [0004] Various studies have been made for clarifying the effects of a histamine-H3 receptor. In animal experiments 45 with rats, a high-level selective inhibitor of histamine synthase (histidine decarboxylase) inhibits the vigilance of rats, which suggests that a histamine-H3 receptor may function for controlling motive vigilance. Administration of a histamine- H3 receptor agonist, (R)-(α)-methylhistamine to cats increases their deep slow-wave sleep (for example, see Brain Research, 523, 325 (1990)). Contrary to this, it has been clarified that a histamine-H3 receptor antagonist or inverse- agonist, thioperamide dose-dependently increases vigilance, and decreases slow-wave and REM sleep (see Science, 50 48,2397 (1991)). This suggests that a histamine-H3 receptor may participate in control of vigilance-sleep, and suggest a possibility that a selective histamine-H3 receptor agonist, or its antagonist or inverse-agonist may be useful for treatment of sleep disorders. Further, in animal experiments with rats, administration of histamine to the ventricle of rats inhibited their eating action, therefore suggesting that histamine may participate in control of eating action (for example, see Research, 793, 279 (1998)), and it has been clarified that thioperamide dose-dependently inhibits eating action and 55 promotes intracerebral histamine liberation (for example, see Life Science, 69, 469 (2001)). These informations suggest that a histamine-H3 receptor may participate in eating action control, further suggesting a possibility that an a histamine- H3 receptor antagonist or inverse-agonist may be useful for prevention or remedy of metabolic diseases such as eating disorder, obesity, diabetes, emaciation, hyperlipemia. In addition, in animal experiments with rats, it has been clarified 3 EP 1 669 350 B1 that administration of a histamine-H3 receptor agonist, (R)-(α)-methylhistamine to rats dose-dependently lowered their basal diastolic pressure, and its action was antagonized by a histamine-H3 receptor antagonist or inverse-agonist, thioperamide (for example, see Journal of Physiology and Pharmacology, 49, 191 (1998)). These informations
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • A2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet Al
    US009078919B2 a2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet al. (45) Date of Patent: *Jul. 14, 2015 (54) MICRO-RNAS OF THE MIR-15 FAMILY 2005/0182011 Al 8/2005 Olson etal. MODULATE CARDIOMYOCYTE SURVIVAL 2006/0058266 Al 3/2006 Manoharan etal. AND CARDIAC REPAIR 2006/0105360 Al 5/2006 Croce etal. 2006/0165659 Al 7/2006 Croceet al. 2006/0185027 Al 8/2006 Bartelet al. (71) Applicant: The Board of Regents, The University 2006/0189557 Al 8/2006 Slack et al. of Texas System, Austin, TX (US) 2006/0247193 Al 11/2006 Taira et al. 2006/0252722 Al 11/2006 Lollo et al. (72) Inventors: Eric N. Olson, Dallas, TX (US); Eva 2007/0026403 Al 2/2007 Hatzigeorgiouetal. 2007/0054287 Al 3/2007 Bloch van Rooij, Utrecht (NL) 2007/0213292 Al 9/2007 Stoffel et al. 2007/0259827 Al 11/2007 Aronin et al. (73) Assignee: The Board of Regents, the University 2007/0287179 Al 12/2007 Tuschletal. of Texas System, Austin, TX (US) 2007/0292878 Al 12/2007 Raymond. 2008/0050744 Al 2/2008 Brownetal. (*) Notice: Subject to any disclaimer, the term of this 2008/0176766 Al 7/2008 Brownetal. 2008/0220423 Al 9/2008 Molleret al. patent is extended or adjusted under 35 2009/0053718 Al 2/2009 Naguibnevaetal. U.S.C. 154(b) by 0 days. 2009/0092980 Al 4/2009 Arenzet al. 2009/0131356 Al 5/2009 Baderet al. This patent is subject to a terminal dis- 2009/0176723 Al 7/2009 Brownetal. claimer. 2009/0214477 Al 8/2009 Betzet al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett Et Al
    USO08080578B2 (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett et al. (45) Date of Patent: *Dec. 20, 2011 (54) METHODS FOR TREATMENT WITH 5,998.458. A 12/1999 Bristow ........................ 514,392 BUCNDOLOL BASED ON GENETIC 6,004,744. A 12/1999 Goelet et al. ...... 435/5 6,013,431 A 1/2000 Söderlund et al. 435/5 TARGETING 6,156,503 A 12/2000 Drazen et al. ..... ... 435/6 6,221,851 B1 4/2001 Feldman ... 51446 (75) Inventors: Stephen B. Liggett, Clarksville, MD 6,316,188 B1 1 1/2001 Yan et al. .......................... 435/6 6,365,618 B1 4/2002 Swartz ... 514,411 (US); Michael Bristow, Englewood, CO 6,498,009 B1 12/2002 Liggett ............................. 435/6 (US) 6,566,101 B1 5/2003 Shuber et al. 435,912 6,586,183 B2 7/2003 Drysdale et al. .................. 435/6 (73) Assignee: The Regents of the University of 6,784, 177 B2 8/2004 Cohn et al. 514,248 Colorado, a body corporate, Denver, 6,797.472 B1 9/2004 Liggett ......... ... 435/6 6,821,724 B1 1 1/2004 Mittman et al. ... 435/6 CO (US) 6,861.217 B1 3/2005 Liggett ......... ... 435/6 7,041,810 B2 5/2006 Small et al. ... ... 435/6 (*) Notice: Subject to any disclaimer, the term of this 7, 195,873 B2 3/2007 Fligheddu et al. ... 435/6 patent is extended or adjusted under 35 7,211,386 B2 5/2007 Small et al. ....... ... 435/6 7,229,756 B1 6/2007 Small et al.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information C om pany 300 North Z eeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800 521-0600 Order Number 9120692 Part 1. Synthesis of fiuorinated catecholamine derivatives as potential adrenergic stimulants and thromboxane A 2 antagonists. Part 2.
    [Show full text]
  • Changes in Blood Pressure, Plasma Catecholamines and Plasma Renin Activity During and After Treatment with Tiamenidine and Clonidine B.G
    Br. J. clin. Pharmac. (1981), 1, 73-77 CHANGES IN BLOOD PRESSURE, PLASMA CATECHOLAMINES AND PLASMA RENIN ACTIVITY DURING AND AFTER TREATMENT WITH TIAMENIDINE AND CLONIDINE B.G. HANSSON Department of Medicine, County Hospital, S - 30185 Halmstad, Sweden B. HOKFELT Department of Endocrinology, University of Lund, Malmo General Hospital, S - 21401 Malmo, Sweden 1 Tiamenidine (Hoe 440) is an imidazoline with blood pressure lowering properties. Its pharma- cology resembles that of clonidine. 2 The effect ofboth drugs on blood pressure, plasma noradrenaline (NA), plasma adrenaline (Ad), urinary catecholamines and plasma renin activity (PRA) was assessed in four previously untreated male hypertensive patients in a cross over study. 3 The maximum daily dose of tiamenidine was 3 mg. The maximum daily dose of clonidine was 450,ug. 4 During treatment, blood pressure, systolic and diastolic, supine and erect, fell on average between 12 and 15%. Levels of NA, Ad, PRA were reduced during treatment. 5 During withdrawal of either drug there was rebound of blood pressure and NA, Ad, PRA, overshooting baseline levels. 6 The withdrawal effects caused by clonidine were similar for tiamenidine. Introduction Tiamenidine is an imidazoline derivative which receptors inhibitory to sympathetic nerve activity. It lowers blood pressure and its pharmacology is an effective hypotensive which does not signifi- resembles that of clonidine. In cat, dog and rabbit, cantly modify homeostatic cardiovascular reflexes. single doses intravenously produce an initial rise in It is now well documented that the cessation of blood pressure followed by a sustained fall (Lindner clonidine therapy may be associated with withdrawal & Kaiser, 1974). In dogs, oral administration pro- phenomena, of which the clinically most serious is a duces a sustained hypotensive effect.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer prfritar. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information Company 300 North Zeeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800/521-0600 Order Number 9211148 Synthesis and biological results of compounds acting on alpha-adrenergic receptors Hong, Seoung Soo, Ph.D. The Ohio State University, 1991 Copyright ©1991 by Hong, Seoung Soo.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0215844 A1 Davis Et Al
    US 20090215844A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0215844 A1 Davis et al. (43) Pub. Date: Aug. 27, 2009 (54) COMPOSITIONS COMPRISING NEBVOLOL (60) Provisional application No. 60/577,423, filed on Jun. 4, 2004. (75) Inventors: Eric Davis, Morgantown, WV (US); John O'Donnell, Morgantown, WV (US); Peter Publication Classification Bottini, Morgantown, WV (US) (51) Int. Cl. A63L/353 (2006.01) Correspondence Address: A6II 3/40 (2006.01) FROST BROWN TODD, LLC A6II 3/4I (2006.01) 2200 PNCCENTER, 201 E. FIFTH STREET CINCINNATI, OH 45202 (US) (52) U.S. Cl. .......... 514/381: 514/456; 514/412: 514/423 (73) Assignee: Mylan Laboratories, Inc., Morgantown, WV (US) (57) ABSTRACT (21) Appl. No.: 12/366,866 Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart (22) Filed: Feb. 6, 2009 failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition Related U.S. Application Data comprising nebivolol and at least one other active agent, (62) Division of application No. 1 1/141,235, filed on May wherein the at least one other active agent is a cardiovascular 31, 2005. agent. Patent Application Publication Aug. 27, 2009 Sheet 1 of 4 US 2009/0215844 A1 Figure 1 50 Black Nebivolol (1.0 M) 500 white + tiebivoloi (1.0 (i)} s Black, Untreated S Swhite, untreated . 9 400 S 350. g 300 5 250 O 200 2. Untreated 1.0 Ramipriat Treatment (um) 'p < 0.05 and tip- 0.01 vs preincubation with nei olo alone (n =6) Patent Application Publication Aug.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,683,231 Glassman (45) Date of Patent: Jul
    United States Patent (19) 11 Patent Number: 4,683,231 Glassman (45) Date of Patent: Jul. 28, 1987 54 METHOD OF PREVENTING WITHDRAWAL (56) References Cited SYMPTOMS ASSOCATED WITH THE U.S. PATENT DOCUMENTS CESSATION OR REDUCTION OF TOBACCO SMOKING 4,575,510 3/1986 Sjoerdsma ........................... 514/813 Primary Examiner-Stanley J. Friedman 75) Inventor: Alexander H. Glassman, Teaneck, Attorney, Agent, or Firm-John P. White 73 Assignee: Research Foundation for Mental 57 ABSTRACT Hygiene, Inc., New York, N.Y. In human subjects accustomed to smoking tobacco the withdrawal symptoms associated with the cessation or 21 Appl. No.: 852,650 reduction of tobacco smoking may be prevented by 22 Filed: Apr. 16, 1986 administering to the subject an effective amount of an alpha-2 adrenergic agonist such as clonidine hydrochlo Related U.S. Application Data ride for a suitable period of time. 62) Division of Ser. No. 585,900, Mar. 2, 1984, Pat. No. Alternatively, such withdrawal symptoms may be pre 4,588,739. vented by administering to such a person an effective amount of alprazolam. 51 Int. Cl." ............................................ A61K 31/395 52 U.S. C. ..................................... 514/220; 514/813 58) Field of Search ................................ 514/813, 220 7 Claims, 2 Drawing Figures U.S. Patent Jul. 28, 1987 Sheet 1 of 2 4,683,231 U.S. Patent Jul. 28, 1987 Sheet 2 of 2 4,683,231 FIGURE 2 OBSESSION WITH CIGARETTES - "CRAVING" 4,683,231 1. 2 BRIEF DESCRIPTION OF THE FIGURES METHOD OF PREVENTING WITH DRAWAL SYMPTOMS ASSOCIATED WITH THE FIG. 1 shows the global ratings obtained at the end of CESSATION OR REDUCTION OF TOBACCO each experiment day, double-bind, assessing the diffi SMOKING culty in not smoking.
    [Show full text]
  • Edited for the British Pharmacological Society By
    Edited for the British Pharmacological Society by C.T. Dollery (Chairman) A. Richens (Secretary) Annmarie Hedges (Press Editor) T.B. Binns A.F. Lant A. Breckenridge G. Mawer W. Watson Buchanan D.G. McDevitt D.B. Caine A.N. Nicholson T. Chard F. O'Grady J. Crooks J.P. Payne D.A.P. Evans B.N.C. Prichard C.F. George M. Rawlins A. Goldberg J. Reid D. Grahame-Smith R.G. Shanks I.W.B. Grant F.O. Simpson R.L. Hodge J.R. Trounce M.H. Lader D.W. Vere O.L. Wade Papers will be considered for publication on all aspects of drug action in man. Manuscripts (two copies) should be sent to Professor A. Richens, Department of Pharmacology and Materia Medica, Welsh National School of Medicine, Heath Park, Cardiff CF4 4XN. The instructions to authors are printed in volume 1 (pages 3 to 6) ofthe journal. Details of the SI symbols for units can be found in the January 1974 issue (volume 50, pages 6 to 23) of the British Journal ofPharmacology. British Journal of Clinical Pharmacology is published monthly by Scientific & Medical Division, Macmillan Publishers Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS. Telephone: Basingstoke 29242. ISSN 0306-5251. Annual subscription: UK £75.00; USA & Canada, US$185; Rest of world, £89; Airmail £102 (or equivalent in any other currency). (Orders must be accompanied by remittance. Prices correct at time of publication.) Cheques should be made payable to Macmillan Journals Limited: Subscription Department, Brunel Road, Basingstoke, Hampshire RG21 2XS, England. Where appropriate, overseas subscribers may make payments into UK Post Office Giro Account No.
    [Show full text]
  • The Effect of Drugs in the Oral Cavity-A Review
    Trophimus Gnanabagyan Jayakaran /J. Pharm. Sci. & Res. Vol. 6(2), 2014, 89-96 The Effect of Drugs in the Oral Cavity - A Review Trophimus Gnanabagyan Jayakaran Saveetha Dental College and Hospitals, Saveetha University, Chennai, India Abstract: It is estimated that more than 2-4% of hospital admissions are related to drug induced reactions. There is an ever expanding list of medications linked to pathologic reactions in the oral and perioral region. Several patterns of diseases have been identified, and these can assist the clinician in determining a possible cause and effect relationship with a particular or a group of drugs. The mechanism of drug induced reaction is not always known or not always predictable since aspects other than pharmacodynamics and/or pharmacokinetics, as well as various interacting variables contribute to the final outcome. Drug induced oral reactions clinically present as Xerostomia, Swelling, Dysguesia, Nonspecific Ulceration, Vesiculobullous or ulcerative mucositis, pigmentation of mucosa, Gingival enlargement, oral malodor, taste alterations, discoloration of teeth. This review gives an update of the various drug induced oral reactions, so that Dentists and oral health professionals increase their knowledge for a better diagnosis and therapy. Key Words: Adverse drug reactions, Oral reactions, Oral manifestations, Mucosal lesions, Drug pharmacodyanamics, INTRODUCTION: bronchodilators, muscle relaxants, methyldopa, laxatives, Several systemic factors are known to contribute to oral betablockers, narcotics, guanabenz, and clonidine. diseases or conditions and among those are the intake of Furthermore the possibility of an underlying autoimmune drugs. An adverse drug reaction is defined by WHO as ‘a etiology(eg. Sjogren Syndrome) should also be considered in response to a drug which is noxious and unintended, and Xerostomic patients, especially those who also present with which occurs at doses normally used in man for the Xerophthalmia or evidence of parotid gland swelling.
    [Show full text]